111437-58-2

Upstream product

• 111437-56-0 N-(benzyloxycarbonyl)-O-allyl-L-serine methyl ester 
• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 107-30-2 chloromethyl methyl ether 
• 111437-57-1 N-(benzyloxycarbonyl)-O-allyl-L-serinol 

Downstream Products

• 111437-55-9 <3R-<3R*,6S*,7(S*)>>-N-amino>-1-oxo-3-phenylpropyl>-6-methyl-5-oxo-1-oxa-4,7-diazacyclotetradec-3-yl>methyl>-L-valyl>-L-isoleucyl>-L-histidine methyl ester 
• 111437-54-8 <3R-<3R*,6S*,7(S*)>>-N-amino>-1-oxo-3-phenylpropyl>-6-methyl-5-oxo-1-oxa-4,7-diazacyclododec-3-yl>methyl>-L-valyl>-L-isoleucyl>-L-histidine methyl ester 
• 106975-94-4 <3R-<3R*,6S*,7(S*)>>-N-amino>-1-oxo-3-phenylpropyl>octahydro-6-methyl-5-oxo-2H-1,4,7-oxadiazecin-3-yl>methyl>-L-valyl>-L-isoleucyl>-L-histidine methyl ester 
• 111437-63-9 pentafluorophenyl 2(S)-methyl-9(S)-<(benzyloxycarbonyl)amino>-3-(tert-butyloxycarbonyl)-3-aza-7,11,13-trioxatetradecanoate 
• 111437-67-3 <3R-<3R*,6S*,7(S*)>>-N-<<7-<2-<<(1,1-dimethylethoxy)carbonyl>amino>-1-oxo-3-phenylpropyl>octahydro-6-methyl-5-oxo-2H-1,4,7-oxadiazecin-3-yl>methyl>-L-valine phenylmethyl ester 
• 111437-76-4 (S)-2-{[(3R,6S)-7-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionyl)-6-methyl-5-oxo-[1,4,7]oxadiazecan-3-ylmethyl]-amino}-3-methyl-butyric acid 
• 111437-62-8 methyl 2(S)-methyl-9(S)-<(benzyloxycarbonyl)amino>-3-(tert-butyloxycarbonyl)-3-aza-7,11,13-trioxatetradecanoate 
• 111437-65-1 <3R-<3R*,6S*,7(S*)>>-<2--2-oxo-1-(phenylmethyl)ethyl>carbamic acid 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

Renin Inhibitors. Design and Synthesis of a New Class of Conformationally Restricted Analogues of Angiotensinogen

Molecular modeling methods have been used to design a novel series of conformationally constrained cyclic peptide inhibitors of human renin.Three goals were defined: enhanced inhibitory potency, high specificity for renin, and increased metabolic stabilit